Research
Hormonal
Ectopic fat accumulation in organs such as the heart, liver, and pancreas is a primary driver of cardiometabolic disease and insulin resistance, often posing a higher risk than classical metrics like BMI.
Focus on reducing visceral and ectopic fat through lifestyle changes rather than just tracking weight. Regular exercise and a balanced diet are effective at reducing hepatic and pancreatic fat, which improves metabolic health even if BMI changes slowly.
GoodSupportsHIGH confidence
Ectopic fat depots within heart, liver, skeletal muscle, kidney, and pancreas as well as around blood vessels might be more associated to cardiometabolic risk than classical variables, such as body mass index.
Why this rating
The paper is a narrative review summarizing multiple observational and interventional studies.
Source
Impact of different ectopic fat depots on cardiovascular and metabolic diseases
Daniele Ferrara et al. · Journal of Cellular Physiology · 2019
DOI 10.1002/jcp.28821
narrative_reviewCited 184×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Epicardial adipose tissue (EAT) and myocardial steatosis contribute to cardiac dysfunction and atrial fibrillation through lipotoxicity, involving the accumulation of diacylglycerols and ceramides.Good
- Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome and a cardiovascular risk factor, driven by lipotoxicity rather than triglycerides alone.Good
- Weight loss, particularly through bariatric surgery or lifestyle interventions, significantly reduces ectopic fat in the liver, pancreas, and heart, improving metabolic health.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →